Klin Farmakol Farm. 2023;37(1):10-18 | DOI: 10.36290/far.2023.002

What is new in the pharmacotherapy of benign prostatic hyperplasia

Jozef Marenčák
Bratislava

Benign prostatic hyperplasia and ensuing lower urinary tract symptoms is a significant health issue affecting millions of men. Many unanswered questions exist including the role of inflammation, metabolic dysfunction, obesity, and environmental factors in etiology, as well as of therapeutic algorithms in both the prevention and progression of disease. The article provides an overview of current and new pharmacotherapy of benign prostatic hyperplasia. Future treatment efforts may utilize more personalized management strategies for this benign disease with a significant negative impact on the quality of life of older men.

Keywords: benign prostatic hyperplasia, pharmacotherapy, monotherapy, combined treatment, new drugs.

Accepted: April 13, 2023; Published: April 21, 2023  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Marenčák J. What is new in the pharmacotherapy of benign prostatic hyperplasia. Klin Farmakol Farm. 2023;37(1):10-18. doi: 10.36290/far.2023.002.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Gravas S, Cornu J, Gacci M, et al. EAU guidelines on management of non-neurogenic male lower urinary tract symptoms (LUTS), incl. benign prostatic obstruction (BPO). [cited 2022 December 15]. Available from: https://uroweb.org/guidelines.
    2. Reynolds W, Strand D. Benign prostatic hyperplasia: etiology, pathophysiology, epidemiology, and natural history. In: Partin A, Dmochowski R, Kavoussi L, et al., editors. Campbell - Walsh Urology, 12th ed. Saunders Elsevier. 2021:3305-3342.
    3. Capogrosso P, Salonia A, Montorsi F. Evaluation and nonsurgical management of benign prostatic hyperplasia. In: Partin A, Dmochowski R, Kavoussi L, et al., editors. Campbell - Walsh Urology, 12th ed. Saunders Elsevier. 2021:3343-3402.
    4. Marenčák J, Mosnárová A. Súčasné možnosti diagnostiky a liečby benígnej hyperplázie prostaty. Kompendium medicíny 1. 2018:2-15.
    5. Lerner L, McVary K, Barry M, et al. Management of lower urinary tract symptoms attributed to benign prostatic hyperplasia: AUA guideline part I - initial work-up and medical management. J Urol. 2021;206(4):806-817. Go to original source... Go to PubMed...
    6. Gravas S, Palacios-Moreno J, Thomson D, et al. Understanding treatment response in individual profiles of men with prostatic enlargement at risk of progression. Eur Urol Focus. 2022. In press https://doi.org/10.1016/j.euf.2022.07.004. Go to original source... Go to PubMed...
    7. Yu Z, Yan H, Xu F, et al. Efficacy and side effects of drugs commonly used for the treatment of lower urinary tract symptoms associated with benign prostatic hyperplasia. Front Pharmacol. 2020;11:658. doi: 10.3389/fphar.2020.00658. Go to original source... Go to PubMed...
    8. Zámečník L. Non-neurogenní poruchy močení u mužů. In: Zámečník et al., editors. Moderní farmakoterapie v urologii. Maxdorf. 2019:171-185.
    9. Gravas S, Bach T, Drake M, et al. Treatment of non-neurogenic male LUTS. In: EAU guidelines on benign prostatic hyperplasia. Arnhem: European Association of Urology. 2017:1-54.
    10. Manohar Ch, Nagabhushana M, Karthikeyan V, et al. Safety and efficacy of tamsulosin, alfuzosin or silodosin as monotherapy for LUTS in BPH - a double blind randomized trial. Cent European J Urol. 2017;70(1):148-153. Go to original source...
    11. Csikós E, Horváth A, Ács K, et al. Treatment of benign prostatic hyperplasia by natural drugs. Molecules. 2021;26(23):7141. doi: 10.3390/molecules26237141. Go to original source... Go to PubMed...
    12. De Nunzio C, Brassetti A, Proietti F, et al. Dutasteride add-on therapy reduces detrusor mass in patients with benign prostatic enlargement not satisfied with alpha-adrenergic antagonist monotherapy: a single center prospective study. Neurourol Urodyn. 2017;36(8):2096-2100. Go to original source... Go to PubMed...
    13. Miernik A, Gratzke Ch. Current treatment for benign prostatic hyperplasia. Dtsch Arztebl Int. 2020;117(49):843-854. Go to original source... Go to PubMed...
    14. Reynolds W, Cohn J. Overactive bladder. In: Partin A, Dmochowski R, Kavoussi L et al., editors. Campbell - Walsh Urology, 12th ed. Saunders Elsevier. 2021:2637-2649.
    15. Kreydin E, Gomes C, Cruz F. Current pharmacotherapy of overactive bladder. Int Braz J Urol. 2021;47(6):1091-1107. Go to original source... Go to PubMed...
    16. Lokeshwar S, Harper B, Webb E, et al. Epidemiology and treatment modalities for the management of benign prostatic hyperplasia. Transl Androl Urol. 2019;8(5):529-539. Go to original source... Go to PubMed...
    17. Marenčák J. Farmakoterapia hyperaktívneho močového mechúra. Klin Urol. 2022;18(3): (v tlači).
    18. Horák A. Současná farmakoterapie benigní hyperplazie prostaty dle doporučení EAU. Urol praxi. 2021;22(3):125-132. Go to original source...
    19. Herbison P, McKenzie J. Which anticholinergic is best for people with overactive blades? A network meta-analysis. Neurourol Urodyn. 2019;38(2):525-534. Go to original source... Go to PubMed...
    20. Nakagomi H, Mitsui T, Shimura H, et al. Mirabegron for overactive bladder in frail patients 80 years or over (HOKUTO study). BMC Urol. 2022;22(1):40. doi: 10.1186/s12894-022-00989-7. Go to original source... Go to PubMed...
    21. Staskin D, Frankel J, Varano S, et al. International-phase III, randomized, doble blind, placebo and active controlled study to evaluate the safety and efficacy of vibegron in patients with symptoms of overactive bladder: EMPOWUR. J Urol. 2020;204(2):316-324. Go to original source... Go to PubMed...
    22. Marenčák J. Erektilná dysfunkcia a jej liečba. Praktické lekárnictvo. 2017;7(2):53-57.
    23. Pattanaik S, Mavuduru R, Panda A, et al. Phosphodiesterase inhibitors for lower urinary tract symptoms consistent with benign prostatic hyperplasia. Cochrane database Syst Rev. 2018;11(11):CD010060. Go to original source... Go to PubMed...
    24. Russo G, Scandura C, Di Mauro M, et al. Clinical efficacy of Serrenoa repens versus placebo versus alpha-blockers for the treatment of lower urinary tract symptoms/benign prostatic enlargement: a systematic review amd network meta-analysis of randomised placebo-contolled clinical trials. Eur Urol Foc. 2021;7(2):420-431. Go to original source... Go to PubMed...
    25. Nagasubramanian S, John N, Antonisami B, et al. Tamsulosin and placebo vs. tamsulosin and tadalafil in male lower urinary tract symptoms: a double-blinded, randomised controlled trial. BJU Int. 2020;125(5):718-724. Go to original source... Go to PubMed...
    26. De Nunzio C, Salonia A, Gacci M, et al. The role of combination therapy with alpha-blockers and hexanic extract Serenoa repens in the treatment of LUTS/BPH. J Clin Med. 2022;11(23):7169. doi: 10.3390/jcm11237169. Go to original source... Go to PubMed...
    27. Roehrborn C, Oyarzabal I, Roos E, et al. Efficacy and safety of a fixed-dose combination of dutasteride and tamsulosin treatment (Duodart®) compared with watchful waiting with initiation of tamsulosin therapy if symptoms do not improve, both provided with lifestyle advice, in the management of treatment-naive men with moderately symptomatic benign prostatic hyperplasia: 2-year CONDUCT study results. BJU Int. 2015;116(3):450-459. Go to original source... Go to PubMed...
    28. Kaplan S, Lee J, Meehan A, et al. Time course of incident adverse experiences associated with doxazosin, finasteride and combination therapy in men with benign prostatic hyperplasia: the MTOPS trial. J Urol. 2016;195(6):1825-1829. Go to original source... Go to PubMed...
    29. Gong M, Dong W, Huang G, et al. Tamsulosin combined with solifenacin versus tamsulosin monotherapy for male lower urinary tract symptoms: a meta-analysis. Curr Med Res Opin. 2015;31(9):1781-1792. Go to original source... Go to PubMed...
    30. Burgio K, Kraus S, Johnson T, et al. Effectiveness of combined behavioral and drug therapy for overactive bladder symptoms in men: a randomized clinical trial. JAMA intern Med. 2020;180(3):411-419. Go to original source... Go to PubMed...
    31. Kaplan S, Herschorn S, McVary K, et al. Efficacy and safety of mirabegron versus placebo add-on therapy in men with overactive bladder symptoms receiving tamsulosin for underlyingbenign prostatic hyperplasia: a randomized, phase 4 study (PLUS). J Urol. 2020;203(6):1163-1171. Go to original source... Go to PubMed...
    32. Chen P, Wang Ch, Tu Y. Combination alpha blocker and phosphodiesterase 5 inhibitor versus alpha blocker monotherapy for lower urinary tract symptoms associated with benign prostate hyperplasia: a systematic review and meta-analysis. Uro Sci. 2020;31(3):99-107. Go to original source...
    33. Yamanishi T, Asakura H, Seki N, et al. A 52 - week randomized comparative study of a triple therapy (tamsulosin, dutasteride, and imidafenacin) versus a dual therapy (tamsulosin and dutasteride) in benign prostatic hyperplasia patients with overactive bladder (DIrecT Study). Eur Urol Suppl. 2017;16(3):e924. Go to original source...
    34. Khizer Z, Sadia A, Sharma R, et al. Drug delivery approaches for managing overactive bladder (OAB): a systematic review. Pharmaceuticals (Basel). 2021;14(5):409. doi: 10.3390/ph14050409. Go to original source... Go to PubMed...
    35. Peyronnet B, Brucker B, Michel M. Lower urinary tract symptoms: what´s new in medical treatment? Eur Urol Foc. 2018;4(1):17-24. Go to original source... Go to PubMed...
    36. Belos T, Tzelves L, Manolitsis I, et al. Frailty and benign prostatic hyperplasia: the thrilling underlying impact. Arch Ital Urol Androl. 2022;94(3):345-349. Go to original source... Go to PubMed...

    Return to the content


    Clinical Pharmacology and Pharmacy

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.